Table 2.

Clinical characteristics of primary AML samples.

AML Sample	Clinical Characteristics	NKG2D-L SFI
1	29yo M; 73% BM blasts; FAB M4-Eo; Complex karyotype with inversion 16. CBFB rearrangement by FISH	1.04
2	49yo F; 21% BM blasts; relapsed FLT-3 mutated AML Normal karyotype and cytogenetics	1.02
3	31yo M; 30% BM blasts; acute erythroid/myeloid leukemia 3q inversion and monosomy 7	0.97
4	45yo F, BM 76% blasts; relapsed AML s/p NMA allo-SCT; 5q deletion	1.08
5	47yo F, 91% BM blasts; secondary t-AML; FAB M1 Near tetraploidy	1.07
6	65yo M; 39% BM blasts, FAB M4 Normal cytogenetics	0.97
7	68yo F; 70% BM blasts, FAB M1 Normal cytogenetics	1.12
8	54yo F; 64% BM blasts; secondary AML arising from MDS	1.05
9	39yo F, 16% BM blasts, FAB M6 (6;9) translocation	1.02
10	55yo M, 22% BM blasts, secondary AML arising from MDS Normal cytogenetics	1.02
11	49yo F; 40% BM blasts; FAB M4 MLL rearranged, FLT-3 WT (negative)	0.88
12	60yo M, 20% BM blasts, relapsed AML, FAB M2 Normal cytogenetics	1.04
13	30yo M, 26% blasts, relapsed AML, FAB M2, FLT-3 ITD+ 13q deletion,	0.93
14	52yo M; BM 43% BM blasts, FAB M2	1.42
15	21yo M; BM 86% blasts, FAB M4 Clonal rearrangement of 7p; 9q deletion.	1.19
16	53yo M, 40% BM blasts; relapsed AML, FAB M4, FLT-3 mutated Normal cytogenetics	1.08
17	53yo M; 42% BM blasts, FAB M2 Normal cytogenetics	1.62
18	23yo F; BM blasts 70% Inversion 16	1.13
19	23yo F; BM blasts 70%; Molecular: FLT-3 ITD+, RUNX1, DNMT3 and ASXL1 mutations Normal cytogenetics	1.06
20	72yo M; 67% BM blasts Normal cytogenetics	1.38
21	67yo M; 50% BM Blasts; FAB M4; Molecular: NMP1 mutated Normal cytogenetics	1.21
22	27yo F; 82% BM blasts; molecular: CEBPA mutation Cytogenetics: trisomy 21	1.04
23	45yo M; 69% BM Blasts, FAB M4-Eo; FLT3 D835 mutation (negative for FLT3-ITD and NPM1) Inversion 16	2.01
24	64yo F; 60% BM blasts; FAB M4 Molecular: DNMT3A, WT1 mutations Cytogenetics: +8	1.18